Encompass Health Corporation
NYSE:EHCMedical - Care Facilities
-$1.95 today
- Market cap
- $13.24B
- Beta
- 0.59
- P/E (TTM)
- 15.9
- EPS (TTM)
- $6.14
- Dividend yield
- 0.76%
Volume 0.84M
Average 0.92M
EHC Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Encompass Health CorporationNYSE: EHC
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization growth accelerates
Q2 FY2026 depreciation & amortization of $90.4M rose 13.1% year over year, ahead of the +9.8% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 3.6% from the prior quarter. Over 3 fiscal years it compounded at +10.4% a year.
Context
- Depreciation & amortization amounted to 5.5% of revenue in FY2025, unchanged from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +13.1% holds above the trailing-twelve-month pace of +9.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 327.9M USD
- Year-over-year change
- +9.4%
- 4-year CAGR
- +10.5%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 327.9M | +9.4% |
| FY2024 | 2024-12-31 | 299.6M | +9.4% |
| FY2023 | 2023-12-31 | 273.9M | +12.4% |
| FY2022 | 2022-12-31 | 243.6M | +10.9% |
| FY2021 | 2021-12-31 | 219.6M | — |
Depreciation & Amortization vs competitors
How EHC compares with its peers on the latest reported figures
- EHC's LTM Jun 2026 depreciation & amortization of $346.5M is the largest of the 9 companies compared; the peer median is $57.78M.
- Its year-over-year change of +9.8% is the 6th highest of 9, against a peer median of +12.6%.
- Depreciation & amortization amounts to 5.6% of revenue for EHC, versus a peer median of 1.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $346.5M | +9.8% | +10.4% | 5.6% | |
| LTM Jun 2026 | $114.56M | +21.9% | +18.7% | 2.1% | |
| LTM Sep 2026 | $73.19M | +7.9% | +2.6% | 1.3% | |
| LTM Jun 2026 | $67.98M | +37.8% | +35.6% | 1.2% | |
| LTM Jun 2026 | $66.42M | +4.1% | +3.1% | 2.6% | |
| LTM Sep 2026 | $49.13M | +10.2% | +3.5% | 3.1% | |
| LTM Oct 2026 | $30.08M | +6.5% | -10.1% | 1.1% | |
| LTM Jun 2026 | $16.71M | +15.1% | +5.3% | 1.1% | |
| LTM Mar 2026 | $12.91M | +93.3% | +20.3% | 1.3% | |
| Peer median (excluding EHC) | $57.78M | +12.6% | +4.4% | 1.3% | |
Competitors are the stored peer set for EHC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 517.6M | 365.9M | 361.6M | 599.4M | 567.2M |
| Depreciation & Amortization | 219.6M | 243.6M | 273.9M | 299.6M | 327.9M |
| Deferred Income Tax | 17.4M | 27.9M | 3.9M | 10.7M | 22.3M |
| Stock-Based Compensation | 29.1M | 29.2M | 50.6M | 48.3M | 0 |
| Change in Working Capital | (118M) | (30.4M) | 50.3M | 21.9M | 4.3M |
| Accounts Receivables | (64.3M) | (16.9M) | (22.4M) | 3M | (15.2M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 14.9M | 2.3M | 11.8M | 3M | (22.6M) |
| Other Working Capital | (68.6M) | (15.8M) | 60.9M | 15.9M | 42.1M |
| Other Non-Cash Items | 50.1M | 69.6M | 110.5M | 22.9M | 253.9M |
| Operating Cash Flow | 715.8M | 705.8M | 850.8M | 1B | 1.18B |
| Capital Expenditures | (551.2M) | (584.1M) | (583.1M) | (642.5M) | (736.4M) |
| Acquisitions (Net) | (118.6M) | 64.1M | 0 | 0 | 0 |
| Purchases of Investments | (9M) | (35.2M) | (23M) | (22.5M) | (184.4M) |
| Sales of Investments | 9M | (64.1M) | 0 | 18.9M | 172.8M |
| Other Investing Activities | 3.5M | (7.7M) | 3.3M | (7.2M) | (14.8M) |
| Investing Cash Flow | (666.3M) | (627M) | (602.8M) | (653.3M) | (762.8M) |
| Debt Repayment | (59.1M) | (498.2M) | (83.3M) | (242M) | (29M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | (14.6M) | (7.3M) | (8.2M) | (31.1M) | (158M) |
| Dividends Paid | (112.2M) | (99M) | (60.4M) | (62.8M) | (71.1M) |
| Other Financing Activities | (54.2M) | 458.8M | (45.3M) | 5.3M | (174.9M) |
| Financing Cash Flow | (240.1M) | (145.7M) | (197.2M) | (330.6M) | (433M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (190.6M) | (66.9M) | 50.8M | 18.9M | (20.2M) |
| Free Cash Flow | 164.6M | 121.7M | 267.7M | 360.3M | 439.2M |
Encompass Health Corporation
NYSE:EHC
Intrinsic Alpha fair value
Locked
Current Price
$134.93
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.